Insulet Corp. Stock
Insulet Corp. Stock
Insulet Corp. gained 0.170% compared to yesterday.
The stock is an absolute favorite of our community with 47 Buy predictions and no Sell predictions.
With a target price of 316 € there is a positive potential of 30.26% for Insulet Corp. compared to the current price of 242.6 €.
So far the community has only identified positive things for Insulet Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Insulet Corp. in the next few years
Pros
?
S********** s********
?
B****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Insulet Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Insulet Corp. | 0.170% | -2.102% | -14.083% | -4.758% | -3.774% | -14.356% | 13.072% |
| Bio-Rad Labs Inc. A | 0.230% | - | - | - | - | - | - |
| Merit Medical Systems | -0.680% | 0.000% | -0.676% | -20.968% | -19.672% | 11.364% | 67.045% |
| Tandem Diabetes Care Inc | -0.940% | 1.805% | 7.391% | -45.819% | -45.434% | -50.650% | -74.866% |
Comments
Insulet (NASDAQ:PODD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for PODD provided by MarketBeat
Insulet (NASDAQ:PODD) had its price target lowered by analysts at Truist Financial Corporation from $412.00 to $390.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PODD provided by MarketBeat
Insulet (NASDAQ:PODD) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $370.00 price target on the stock.
Show more
Ratings data for PODD provided by MarketBeat
News
Insulet (PODD) Q2 Revenue Jumps 33%
Insulet (NASDAQ:PODD), a medical device company specializing in wearable insulin delivery systems, released its second quarter 2025 earnings on August 7, 2025. The headline news was strong
